Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020198125 - PROCÉDÉS DE TRAITEMENT D'UN CANCER COLORECTAL

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

WHAT IS CLAIMED IS:

1. A method for treating colorectal cancer, the method comprising administering to a human subject diagnosed with colorectal cancer a first composition comprising a mitogen-activated protein kinase/extracellular signal -regulated kinase

(MAPK/ERK) kinase (MEK) inhibitor and a second composition comprising a bisphosphonate.

2. The method of claim 1, wherein the colorectal cancer is KRAS-mutant colorectal cancer.

3. The method of claim 1, wherein the colorectal cancer is KRAS-mutant colorectal adenocarcinoma cancer.

4. The method of claim 1, wherein the colorectal cancer is NRAS-mutant or HRASmutant colorectal cancer.

5. The method of claim 1, wherein the colorectal cancer contains a gene isoform previously demonstrated to activate KRAS, HRAS, or NRAS.

6. The method of any one of claims 1 to 5, wherein the MEK inhibitor is trametinib.

7. The method of any one of claims 1 to 5, wherein the MEK inhibitor is trametinib dimethyl sulfoxide.

8. The method of claim 6 or 7, wherein the first composition is a tablet.

9. The method of claim 7, wherein the first composition is MEK TNT ST®

10. The method of any one of claims 1 to 5, wherein the MEK inhibitor is cobimetinib.

11. The method of any one of claims 1 to 5, wherein the MEK inhibitor is cobimetinib fumarate.

12. The method of claim 10 or 11, wherein the first composition is a tablet.

13. The method of claim 11, wherein the first composition is COTELLIC®.

14. The method of any one of claims 1 to 5, wherein the MEK inhibitor is binimetinib.

15. The method of claim 14, wherein the first composition is a tablet.

16. The method of claim 14, wherein the first composition is MEKTOVI®.

17. The method of any one of claims 1 to 5, wherein the MEK inhibitor is CI-1040 (PD 184352), PD0325901, Selumetinib (AZD6244), MEK162, AZD8330, TAK-733, GDC-0623, Refametinib (RDEA1 19; BAY 869766), Pimasertib (AS703026), R04987655

(CH4987655), R05126766, WX-554, HL-085, E6201, GDC-0623, or PD098059.

18. The method of claim 17, wherein the first composition is a tablet.

19. The method of any one of claims 1 to 18, wherein the first composition is orally administered to the subject.

20. The method of any one of claims 1 tol9, wherein the bisphosphanonate is etidronate, alendronate, risedronate, ibandronate, zoledronic acid, alendronate sodium, clodronate, tiludronate, pamidronate, neridronate, or olpadronate.

21. The method of claim 20, wherein the bisphosphonate is zoledronic acid.

22. The method of claim 21, wherein the second composition is Zometa®.

23. The method of claim 20, wherein the bisphosphonate is ibandronate.

24. The method of claim 23, wherein the second composition is BONIV A®

25. The method of any one of claims 1 to 24, wherein the second composition is administered to the subject intravenously or orally.

26. The method of any one of claims 1 to 25, wherein the subject is unresponsive to other therapies approved for colorectal cancer.

27. The method of any one of claims 1 to 26, wherein the dosage of the MEK inhibitor and the dosage of the bisphosphonate are the dosages approved by the U.S. Food and Drug Administration for any use.